Normalization of elevated liver enzymes due to V-1 Immunitor therapy

Metadatas

Date

April 1, 2003

type
Language
Identifier
Organization

SciELO

License

info:eu-repo/semantics/openAccess



Cite this document

Vichai Jirathitikal et al., « Normalization of elevated liver enzymes due to V-1 Immunitor therapy », Electronic Journal of Biotechnology, ID : 10670/1.x6g1a1


Metrics


Share / Export

Abstract 0

V-1 Immunitor (V1) is an oral AIDS vaccine currently being used as a therapeutic modality by HIV-positive patients. Upon interim analysis of phase I safety trial it has been discovered that patients who had elevated liver enzymes aspartate (AST/SGOT) and alanine (ALT/SGPT) aminotransferases have experienced the reduction of enzyme levels back to normal. Two other hepatitis markers alkaline phosphatase and bilirubin have also decreased. V1’s effect may be hepatitis-specific since liver enzymes in normal patients treated with V1 have not changed and three patients who were Hepatitis B antigen positive at baseline became negative after therapy. The results suggest that V1 supplementation reduces hepatic damage caused by hepatitis viral infection.

From the same authors

On the same subjects

Similar documents